How do you reduce healthcare costs, improve treatment and support critical research into biomedicine at the same time? You create a decentralized platform to digitize resources, of course.

Say hello to BioLife — the new venture that’s making these potentialities a reality.

Launched by Swiss Vitality Cells Laboratory Limited, BioLife is built on the consortium chain group based on ACChain bottom layer technology. It is an on-chain asset digitization tool for owners of bioscience resources (like pharmaceutical companies, biomedical institutions, and service providers) to digitize resources and for patients to control their own electronic health records.

This digitization process connects patients and biomedical asset owners like never before, across borders, across disciplines and even across time by creating new research opportunities and making new treatments more readily available.

The BioLife service platform is the main tool for interaction with the project, providing digital rights for owners of bioscience resources. Assets are then changed into biomedical digital assets and circulated online. Moreover, BioLife offers a health services channel of traceability, security, convenience and confidentiality to patients who receive bioscience resources and it provides access to the world’s best biomedical solutions and health service products.

BioLife sets up a credit ledger for every owner of health service resources and builds a private health ledger for every patient. Data is exchanged peer-to-peer without any intermediate parties. No more medical records that can’t be taken to and used by doctors in multiple countries.

This system of ledgers also finally realizes the dream of having a large, reliable set of medical patient data that can be used in research and improving treatments.

Operation and management of BioLife is ultimately governed by BioLife’s decentralized autonomous community (DAC) supported by smart contracts that make decisions regarding the future direction of the platform.

Eighty biomedical products produced by Swiss Serolab of Leukerbad Wellness Management Group LTD will be digitized upon launch of the BioLife service platform, which will create an entirely new level of traceability with respect to medicine. In the meantime, eight global node service agents of Swiss Serolab will support BioLife’s token (BIOT) and biomedical digital asset consumption on the BioLife service platform.

In the future, additional parties will be joining the BioLife ecosystem to provide diversified services of healthcare.

BioLife also plans to service additional bioscience health agents and assist with the traceability of the entire process of medication and treatment. It will also offer global participants of the BioLife services platform with added varieties of treatment. In addition, BioLife will be dedicated to medical research and it will validate the ownership of biomedical achievements, rewards and knowledge sharing.

BioLife is all about bringing the benefits of digitization to biomedicine, and it’s built to do precisely that.